Ordinary Index Rebalancing in the Solactive Pharma & Biotech Opportunity Index | August 2019

In the ordinary rebalance the following composition will be implemented:

3SBIO INC
ALKERMES PLC
ARENA PHARMACEUTICALS INC
BLUEBIRD BIO INC
CARDINAL HEALTH INC
CELLTRION HEALTHCARE CO LTD
CHINA BIOLOGIC PRODUCTS HOLD
CHINA MEDICAL SYSTEM HOLDINGS LTD
CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO LTD
EMERGENT BIOSOLUTIONS INC
EXELIXIS INC
H LUNDBECK AS
HIKMA PHARMACEUTICALS PLC
HORIZON THERAPEUTICS PLC
HYPERA SA
IPSEN SA
JAZZ PHARMACEUTICALS PLC
LUYE PHARMA GROUP LTD
MEDPACE HOLDINGS INC
MYOKARDIA INC
NEKTAR THERAPEUTICS
ONO PHARMACEUTICAL CO LTD ORD
SAMSUNG BIOLOGICS CO LTD
SAWAI PHARMACEUTICAL CO LTD ORD
SINO BIOPHARMACEUTICAL LTD ORD
SINOPHARM GROUP CO LTD
SWEDISH ORPHAN BIOVITRUM AB
SYNEOS HEALTH INC
XENCOR INC
YUHAN CORP ORD